• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Deleterious variants in the autophagy-related gene RB1CC1/FIP200 impair immunity to SARS-CoV-2

tetano

Editor, Senior Moderator
Nat Commun


. 2025 Nov 27;16(1):10618.
doi: 10.1038/s41467-025-65308-8. Deleterious variants in the autophagy-related gene RB1CC1/FIP200 impair immunity to SARS-CoV-2

Lili Hu[SUP] 1 2 [/SUP], Renee M van der Sluis[SUP] #[/SUP][SUP] 1 2 [/SUP], Kennith Brian Castelino[SUP] #[/SUP][SUP] 1 [/SUP], Bao-Cun Zhang[SUP] 1 2 [/SUP], Andreas Ronit[SUP] 3 [/SUP], Thomas Zillinger[SUP] 1 2 [/SUP], Marvin Werner[SUP] 1 2 [/SUP], Sofie Eg Jørgensen[SUP] 1 2 [/SUP], Anne Louise Hansen[SUP] 1 [/SUP], Alice Pedersen[SUP] 1 [/SUP], Ryo Narita[SUP] 1 2 [/SUP], Line S Reinert[SUP] 1 2 [/SUP], Bettina Bundgaard[SUP] 1 2 [/SUP]; COVID Human Genetic Effort; Christian K Holm[SUP] 1 [/SUP], Aurelie Cobat[SUP] 4 5 6 [/SUP], Jean-Laurent Casanova[SUP] 4 5 6 7 8 [/SUP], Fulvio Reggiori[SUP] #[/SUP][SUP] 1 [/SUP], Muriel Mari[SUP] #[/SUP][SUP] 1 [/SUP], Søren R Paludan[SUP] 1 2 [/SUP], Trine H Mogensen[SUP] 9 10 11 [/SUP]



Collaborators, Affiliations
Abstract

The clinical outcome of SARS-CoV-2 infection spans from asymptomatic viral elimination to lethal COVID-19 pneumonia, which is due to type I interferon (IFN) deficiency in at least 15-20% of cases. We report two unrelated male patients with critical COVID-19 who are heterozygous for rare deleterious variants in RB1CC1, encoding the autophagy-related FIP200 protein. Airway epithelial cells genetically deprived of FIP200 or cell lines expressing the RB1CC1/FIP200 patient variants exhibit elevated SARS-CoV-2 replication and impaired autophagic flux. The antiviral function of FIP200 is independent of canonical autophagy and type I IFN, but involves the selective autophagy receptor NDP52. We identify a non-canonical function of FIP200 in a novel lysosomal degradation pathway, in which SARS-CoV-2 virions are targeted to single-membrane compartments for degradation of viral RNA in LC3B-positive acidified vesicles. This pathway is impaired in FIP200-deficient cells and in cells expressing FIP200 patient haplotypes. Collectively, we describe a cell-autonomous anti-SARS-CoV-2 restriction pathway, dependent on FIP200 and NDP52, and independent of canonical autophagy and type I IFN, which can underlie critical COVID-19 pneumonia.


 
Back
Top Bottom